Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

MET and ALK as targets for the treatment of NSCLC.

Capelletti M, Gelsomino F, Tiseo M. MET and ALK as targets for the treatment of NSCLC. Curr Pharm Des. 2014; 20(24):3914-32.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.